NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2021 and updated 2021 financial guidance.
Maravai LifeSciences reported a strong third quarter with revenue increasing by 133% to $204.8 million and net income of $132.8 million, representing a 240% growth over the prior year. The company also increased its 2021 revenue guidance to a range of $770.0 million to $780.0 million and established initial 2022 revenue guidance range of $840.0 million to $880.0 million.
- Revenue increased 133% to $204.8 million for the third quarter.
- Net income of $132.8 million for the third quarter, representing growth of 240% over the prior year.
- 2021 revenue guidance increased to a range of $770.0 million to $780.0 million.
- Established initial 2022 revenue guidance range of $840.0 million to $880.0 million.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$203M
Revenue by segment
Maravai · $200M total across 2 segments · Q3 2021
- TriLink$183M+170.3%91.7%
- Cygnus$16.6M+17.8%8.3%
Forward guidance
Maravai provided preliminary revenue guidance for 2022, projecting total revenue to be in the range of $840.0 million to $880.0 million, reflecting overall growth at the midpoints of 11% and 14% before and after adjusting for the divestiture of our Protein Detection Business, respectively.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+1.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.4% | +10.9% | +27.5% | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro